Nahas SJ, Zhao Y, Graham CN, Erbe A, Blumenfeld A. Comparative efficacy of AXS-07 vs. gepants for acute treatment of migraine: a network meta-analysis. Poster presented at the American Academy of Neurology (AAN) 2025 Annual Meeting; April 2025.
Pritchard C, Kutikova L, Pitman R, Lai KZH, Beyhaghi H, Gibbons I, Erbe A, Zivkovic-Gojovic M, Cosgrove C, Sculpher M, Salisbury D. Cost-effectiveness of introducing nuvaxovid to COVID-19 vaccination in the United Kingdom: a dynamic transmission model. Vaccines (Basel). 2025 Feb 14;13(2):187. doi: 10.3390/vaccines13020187
Graham C, Erbe A. Hospitalization costs of common grade 3/4 adverse events associated with oncology treatments in the United States: 2024 update. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S137. doi: 10.1016/j.jval.2024.03.730
Graham CN, Erbe AW. Hospitalization costs of common grade 3/4 adverse events associated with oncology treatments in the United States. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S137. doi: 10.1016/j.jval.2024.03.730
Erbe AW, Kendzia D, Busink E, Carroll S, Aas E. Value of an integrated home dialysis model in the United Kingdom: a cost-effectiveness analysis. Value Health. 2023 Jul;26(7):984-94. doi: 10.1016/j.jval.2023.02.009